Australia's most trusted
source of pharma news
Sunday, 01 June 2025
Posted 16 May 2025 PM
Roche has been the subject of a scathing public telling off by a senior White House official for daring to speak out about the potential impact of recent policy announcements by US President Donald Trump.
It followed concerns aired by Roche that its planned US$50 billion investment in R&D, manufacturing and diagnostics in the US could be impacted by Trump policy.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.